Department of Technology Advancement and Commercialization, RTI International, Research Triangle Park, North Carolina, USA.
Division: Scientific Core Laboratories; Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA.
J Aerosol Med Pulm Drug Deliv. 2024 Apr;37(2):77-89. doi: 10.1089/jamp.2023.0041. Epub 2024 Jan 17.
Animal studies are an important component of drug product development and the regulatory review process since modern practices have been in place, for almost a century. A variety of experimental systems are available to generate aerosols for delivery to animals in both liquid and solid forms. The extrapolation of deposited dose in the lungs from laboratory animals to humans is challenging because of genetic, anatomical, physiological, pharmacological, and other biological differences between species. Inhaled drug delivery extrapolation requires scrutiny as the aerodynamic behavior, and its role in lung deposition is influenced not only by the properties of the drug aerosol but also by the anatomy and pulmonary function of the species in which it is being evaluated. Sources of variability between species include the formulation, delivery system, and species-specific biological factors. It is important to acknowledge the underlying variables that contribute to estimates of dose scaling between species.
动物研究是药物产品开发和监管审查过程的重要组成部分,因为现代实践已经存在了近一个世纪。有多种实验系统可用于生成液体和固体形式的气溶胶,以递送到动物体内。由于物种之间存在遗传、解剖、生理、药理和其他生物学差异,因此从实验室动物推断肺部沉积剂量具有挑战性。由于空气动力学行为及其在肺部沉积中的作用不仅受到药物气溶胶的性质影响,还受到评估中物种的解剖结构和肺功能的影响,因此吸入药物输送的外推需要仔细审查。物种间存在变异性的来源包括制剂、输送系统和物种特异性的生物学因素。重要的是要承认导致物种间剂量比例估计的潜在变量。